Development of novel first-in-class small molecules targeting  transcription-replication conflict for HRD (BRCA) solid tumors

First-in-class small molecules derived from tropical plant natural products for HRD (e.g. BRCA) cancer patients and carriers

Our unique, natural product-inspired drug discovery process has been incredibly successful in identifying a promising lead molecule, (NB1001) derived from a tropical medicinal plant from Singapore and Malaysia. NB1001 have been engineered with its derivative (NB1002) to exhibit enhanced potent anti-cancer activity, effectively instigating synthetic lethality                                  through Transcription-Replication Conflicts in Homologous Recombination Deficiency (HRD) cancers (E.g Triple Negative BRCA (-/-) Breast Cancer)                . As our preclinical experiments suggest, NB1001 and NB1002  can be applied across the spectrum of cancers exhibiting HRD, it offers an opportunity to revolutionize the approach towards cancer treatment. For HRD or BRCA mutation carriers (High Risk Group), this mechanism offers a prophylactic barrier, pre-emptively targeting potential malignant transformations                .